Img Dry	2010	1636\$
2 2 2003 E DEC 2 3 20	U.S. Paten	PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number.
DYLIGI BY	Application Number	09/990,522
TRANSMITTA BADE	Filing Date	November 21, 2001
FORM	First Named Inventor	Choy-Pik Chiu, et al.
(to be used for all correspondence after initial (Art Unit	1636
·	Examiner Name	Quang Nguyen
Total Number of Pages in This Submission	6 Attorney Docket Number	097/002
	ENCLOSURES (Check all that	t apply)
Fee Transmittal Form (in duplicate) Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement (2 pages) Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks 1. PTO Form 1449 (1 page) + co	Other Enclosure(s) (please Identify below):
SIGNA	TURE OF APPLICANT, ATTORNI	EY. OR AGENT
Firm or Individual name Signature	J. Michael Schiff, Registra	•
57	December 19, 200	3
I hereby certify that this correspondence is be		deposited with the United States Postal Service with tents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name	/ KARTX MAKAUSA	y
Signature	Amakausky	Date December 19, 2003

This collection of information is required by 37 CFR 1.5. The information is required to btain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-03) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known **Application Number** 09/990,522 November 21, 2001 Filing Date Choy-Pik Chiu, et al. First Named Inventor Effective 10/01/2003. Patent fees are subject to annual revision. Quang Nguyen **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1636 180 **TOTAL AMOUNT OF PAYMENT** (\$) 097/002 Attorney Docket No. METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) Money Order 3. ADDITIONAL FEES Credit card Other Large Entity | Small Entity ✓ Deposit Account: Fee Fee Fee Description Deposit (\$) Code Code Fee Paid 07-1139 Account 1051 130 2051 65 Surcharge - late filing fee or oath Number Deposit 1052 50 2052 Surcharge - late provisional filing fee or Geron Corporation Account cover sheet Name 1053 130 1053 130 Non-English specification The Director is authorized to: (check all that apply) 1812 2.520 For filing a request for ex parte reexamination 1812 2,520 Charge fee(s) indicated below Credit any overpayments 1804 920 1804 Requesting publication of SIR prior to Charge any additional fee(s) or any underpayment of fee(s) Examiner action Charge fee(s) indicated below, except for the filing fee 1805 1,840 1805 1.8401 Requesting publication of SIR after Examiner action to the above-identified deposit account. Extension for reply within first month 1251 110 2251 **FEE CALCULATION** 1252 420 2252 210 Extension for reply within second month 1. BASIC FILING FEE 950 2253 1253 475 Extension for reply within third month arge Entity Small Entity Fee ree Code (\$) Fee Description Fee Paid 2254 1254 1.480 740 Extension for reply within fourth month Code (\$) 1,005 Extension for reply within fifth month 1255 2.010 2255 1001 770 2001 385 Utility filing fee 1401 330 2401 165 Notice of Appeal 1002 340 2002 170 Design filing fee 330 2402 1402 165 Filing a brief in support of an appeal 1003 530 2003 265 Plant filing fee 1403 290 2403 145 Request for oral hearing 1004 770 2004 385 Reissue filing fee 1451 1.510 1451 1,510 Petition to institute a public use proceeding 1005 160 2005 80 Provisional filing fee 1452 110 2452 55 Petition to revive - unavoidable **SUBTOTAL (1)** (\$) 0 1453 1,330 2453 665 Petition to revive - unintentional 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1501 1,330 2501 665 Utility issue fee (or reissue) Fee from Extra Claims Fee Paid 1502 480 2502 240 Design issue fee **Total Claims** Х -20** 1503 640 2503 320 Plant issue fee Independent

1460 130 1460 130 Petitions to the Commissioner Multiple Dependent 50 1807 50 Processing fee under 37 CFR 1.17(q) 1807 Large Entity Small Entity 180 180 180 Submission of Information Disclosure Stmt 1806 1806 Fee Fee Fee Fee Fee Description 40 Recording each patent assignment per Code (\$) Code (\$) 8021 40 8021 property (times number of properties) Claims in excess of 20 1202 18 2202 9 385 Filing a submission after final rejection (37 CFR 1.129(a)) 1809 770 2809 1201 86 2201 43 Independent claims in excess of 3 1203 290 2203 Multiple dependent claim, if not paid 145 385 For each additional invention to be examined (37 CFR 1.129(b)) 1810 770 2810 ** Reissue independent claims 1204 86 2204 over original patent 1801 770 2801 385 Request for Continued Examination (RCE) ** Reissue claims in excess of 20 1802 900 1802 900 Request for expedited examination 1205 18 2205 9 of a design application and over original patent Other fee (specify) SUBTOTAL (2) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) 180 (\$) **or number previously paid, if greater; For Reissues, see above

WARNING: Information on this form may become public. Credit card information should not be included on this form. Plovide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Registration No.

40,253

(Complete (if applicable))

(650) 473-7715

103

Telephone


Date

J. Michael Schiff

SUBMITTED BY

Name (Print/Type)

Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Choy-Pik Chiu & Robert Kay

Filing Date: November 21, 2001

Serial No: 09/990,522

Docket: 097/002

Title: TOLERIZING ALLOGRAFTS OF

PLURIPOTENT STEM CELLS

Art Unit: 1636

Examiner: Quang Nguyen, Ph.D.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR § 1.97(c)(2)

Commissioner for Patents & Trademarks Washington, D.C. 20231

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

This Information Disclosure Statement is being filed after the first Office Action on the merits, pursuant to 37 CFR § 1.197(c)(2). Authorization to charge Deposit Account 07/1139 with the fee therefor under 37 CFR § 1.117(p) is provided in the accompanying fee calculation sheet.

Should any other fees be required for further consideration of the application, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to the Deposit Account.

Respectfully submitted,

J. Michael Schiff

Registration No. 40,253

GERON CORPORATION 230 Constitution Drive Menlo Park, CA 94025 Telephone: (650) 473-7715

Fax: (650) 473-8654

December 18, 2003

Inf rmati n Discosur Statement By Applicant Filing Date: November 21, 2001 Group: 1636 Exam

U.S. Patent D cuments

Examiner: Q. Nguyen

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
	FA	6,368,636	Oct 26/99	Apr. 9/02	424/577	McIntosh et al.	Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
	ĺ						

Foreign Patent or Published Foreign Patent Application

Examiner Initial	Ref.	Document No.	Publ. Date	Juris- diction	Title:	Trans Yes	lation No
					(NONE)		

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
	FB	Barber et al. Long-term reults of a controlled prospective stuty with transfucion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51:70, 1991. (abstract)
	FC	Fontes et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancras islet transplantation. Lancet 344(8916):151, 1994. (abstract)
	FD	Kuhr et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 73:1487, 2002.
	FE	Menaché et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41:1078, 2003.
	FF	Rifle & Mousson. DOnor-derived hematopoietic cells in organ transplantation: A major step toward allograft tolerance? Transplantation 75 Suppl: 3S, 2003.
	FG	Seung et al. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J. Clin. Invest. 112:795, 2003.
	FH	Wekerle et al. Mechanisms of tolerance induction through the treansplantation of donor hematopoietic stem cells: Central versus peripheral tolerance. Transplantation 75 suppl:21S, 2003.
	FI	Xu et al. Characterization and enrichment of cardiomyocytes derived form human embryonic stem cells. Circ. Res. 91:501, 2002.
	FJ	Yao et al. Long-term outcome of fetal cell transplantation on postinfarctoin ventricular remodeling and function. J. Molec. Cell. Cardiol. 35:661, 2003.

Examiner	Date Considered